Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
Holding IVVD?
Track your performance easily
Earnings Data
Report Date
Mar 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.3Last Year’s EPS
-$0.67Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -50.22%
|Next Earnings Date:Mar 27, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with significant achievements in clinical results and product growth being overshadowed by commercial headwinds and the withdrawal of revenue guidance.Company Guidance
In the Q3 2024 earnings call for Invivyd, the company provided financial guidance indicating that they expect to end the year with at least $65 million in cash and cash equivalents. They reported $9.3 million in net product revenue for Q3 from PEMGARDA, an antibody for SARS-CoV-2, and announced a September cash balance of approximately $107 million. While the company withdrew earlier guidance of $150 million to $200 million in net product revenue due to headwinds from an FDA warning, they expect to achieve profitability by June 2025, driven by operational efficiencies and anticipated revenue growth. The call emphasized their strategy of maintaining minimal manufacturing expenses in the near term, given a significant inventory already on hand, and highlighted a focus on driving commercial success and expanding access to PEMGARDA for immunocompromised individuals.Positive Clinical Trial Results
The CANOPY Phase III clinical trial demonstrated an 80% to 90% reduction in the risk of symptomatic COVID-19 with pemivibart, showing strong protection over multiple variant waves and lineages.
Strong Product Growth Indicators
Despite headwinds, there has been a recent return to product growth, with increased sales and strategic expansions in the immunocompromised market.
Launch of VYD2311
First-in-human study of VYD2311 began, assessing various dosing routes with potential for improved drug profile over pemivibart.
---
IVVD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IVVD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $0.89 | $0.79 | -11.24% |
| Aug 14, 2024 | $1.06 | $0.98 | -7.55% |
| May 09, 2024 | $2.42 | $2.26 | -6.61% |
| Mar 28, 2024 | $4.00 | $4.44 | +11.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Invivyd (IVVD) report earnings?
Invivyd (IVVD) is schdueled to report earning on Mar 27, 2025, TBA Not Confirmed.
What is Invivyd (IVVD) earnings time?
Invivyd (IVVD) earnings time is at Mar 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IVVD EPS forecast?
IVVD EPS forecast for the fiscal quarter 2024 (Q4) is -$0.3.
---